Hand Transplant in India and UAE | Complete Patient Guide

• IDEAL CANDIDATES:

• Unilateral or bilateral hand amputees resulting from traumatic avulsion, blast injury, crush injury, burns, or malignancy resection, where prosthetic rehabilitation has failed to restore functional satisfaction

• Patients aged 18–55 years (younger recipients show superior nerve regeneration rates; age >60 is a relative contraindication due to slower axonal regrowth and higher immunosuppression-related comorbidity risk)

• Amputation level at or distal to the mid-forearm (transcarpal, wrist disarticulation, or below-elbow stumps with preserved forearm musculature provide the best functional substrates)

• Patients who have demonstrated psychological stability, realistic expectations, high motivation for intensive rehabilitation (minimum 2 years), and compliance with lifelong immunosuppression

• BMI ≤ 32 kg/m² (obesity increases surgical complexity and wound complication rates)

• Non-smokers or confirmed ex-smokers (≥ 6 months cessation); nicotine causes microvascular vasoconstriction and significantly elevates thrombosis risk in anastomosed vessels

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• Complete HLA typing (Class I: HLA-A, B, C; Class II: HLA-DR, DQ, DP) and ABO/Rh blood group confirmation

• Lymphocyte cross-match (complement-dependent cytotoxicity and flow cytometry) — must be negative

• Panel Reactive Antibody (PRA) screen to quantify pre-formed donor-specific antibodies (DSA); high PRA (>20%) may require desensitization

• Contrast-enhanced CT angiography (CECT) of the stump/residual limb vasculature to assess radial/ulnar artery patency and caliber

• Nerve conduction studies (NCS) and electromyography (EMG) of residual forearm musculature to confirm viable motor unit recruitment

• Full cardiac evaluation: ECG, transthoracic echocardiography (ECHO), and stress test if age >40 or cardiac history, to assess fitness for prolonged general anesthesia (8–14 hours)

• Renal function panel (eGFR, serum creatinine), liver function tests, HbA1c — baseline organ reserve essential before tacrolimus initiation

• Infectious disease screening: HIV, Hepatitis B (HBsAg, anti-HBc), Hepatitis C (anti-HCV + PCR), CMV IgG/IgM, EBV, TB (Quantiferon-TB Gold or Mantoux)

• Psychiatric evaluation using validated tools (MMPI-2, SCL-90) and formal psychosocial assessment by a transplant psychologist

• Bone density scan (DEXA) if long-term corticosteroid use is anticipated

• ABSOLUTE CONTRAINDICATIONS:

• Active malignancy or remission < 5 years for most solid tumors

• Severe cardiovascular disease with EF < 35% or unrevascularizable coronary artery disease

• Uncontrolled diabetes mellitus (HbA1c > 9%) or severe diabetic vasculopathy

• Active systemic infection, sepsis, or untreated TB

• Significant psychiatric illness that precludes informed consent or reliable medication adherence (active schizophrenia, severe untreated bipolar disorder)

• Severe coagulopathy or bleeding disorder incompatible with anticoagulation management

• Known allergy or hypersensitivity to required immunosuppressants

• Patients unwilling to accept lifelong immunosuppression and its attendant risks

MICROSURGICAL TECHNIQUE — THE CORE PROCEDURE:

Hand transplantation is performed under general anesthesia with continuous arterial line and central venous monitoring. The surgical team (typically 8–14 surgeons and technicians working in relay) proceeds through sequential anatomical layers:

1. Skeletal fixation: Donor and recipient bone ends are prepared and fixed using low-profile locking compression plates (LCP) or intramedullary fixation at the radius/ulna or metacarpal level. Rigid bony union is the foundation for subsequent tissue repair and early rehabilitation.

2. Tendon repair: Flexor digitorum profundus (FDP), flexor digitorum superficialis (FDS), and extensor tendons are repaired using modified Kessler or Adelaide four-strand core sutures with peripheral epitendinous running sutures, optimized for gliding strength.

3. Arterial anastomosis: Radial and ulnar arteries are repaired under operating microscope (×10–×16 magnification) using 8-0 or 9-0 monofilament nylon interrupted sutures, with pharmacological vasodilation (papaverine, lidocaine irrigation) and systemic heparinization (ACT-guided) to prevent thrombosis. Doppler ultrasound confirms pulsatile flow immediately post-anastomosis.

4. Venous anastomosis: A minimum of two dorsal venae comitantes per artery are repaired to ensure adequate drainage and prevent venous congestion, the leading cause of early graft loss.

5. Nerve coaptation: Median, ulnar, and radial nerves are repaired under high magnification using epineurial sutures (9-0 or 10-0 nylon) or, where significant tension exists, donor nerve conduits or acellular nerve allografts (e.g., AxoGen Avance) to bridge gaps without tension. Fascicular or group fascicular repair is used where nerve anatomy permits.

6. Skin closure: Meticulous layered skin closure with preservation of superficial venous and lymphatic channels. Skin grafting may be required at the stump-donor interface.

BILATERAL HAND TRANSPLANTATION:

For bilateral amputees, the same sequence is performed simultaneously by two separate surgical teams on each limb, extending total operative time to 14–18 hours. Bilateral recipients gain greater independence benefit but face doubled immunological exposure and higher surgical risk.

INTRAOPERATIVE MONITORING TECHNOLOGIES:

• Indocyanine green (ICG) fluorescence angiography to confirm perfusion patterns in the transplanted hand

• Implantable Doppler probes (Cook-Swartz) placed on anastomosed vessels for continuous post-operative vascular monitoring in the ICU

• Near-infrared spectroscopy (NIRS) for real-time tissue oxygenation monitoring

DONOR LIMB PRESERVATION:

Cold ischemia time should be minimized to < 6 hours (ideally < 4 hours). Preservation solutions (University of Wisconsin solution or Custodiol HTK) are used for flush and static cold storage. Machine perfusion protocols for limb allografts are under investigation at leading centers.

IMMUNOSUPPRESSION PROTOCOLS:

Triple immunosuppression is initiated at the time of reperfusion:

• Tacrolimus (FK506): target trough 10–15 ng/mL (Year 1), tapering to 8–12 ng/mL thereafter; monitored twice weekly initially, then monthly

• Mycophenolate Mofetil (MMF): 1–1.5 g twice daily, adjusted for GI tolerance and WBC count

• Prednisolone: 1 mg/kg/day tapered to 5–10 mg/day maintenance by Month 3

• Induction: Basiliximab (20 mg on Day 0 and Day 4) OR rabbit ATG (1.5 mg/kg/day for 5 days) for high-risk recipients

ACUTE REJECTION MANAGEMENT:

Banff Grade I/II acute cellular rejection (the most common, characterized by perivascular lymphocytic infiltration on skin punch biopsy) is managed with pulse IV methylprednisolone (500 mg × 3 days) and tacrolimus dose escalation. Steroid-refractory rejection may require ATG or plasmapheresis for antibody-mediated rejection (AMR).

EMERGING APPROACHES:

• Tolerance induction protocols: Bone marrow co-transplantation from the same donor (combined BMT + VCA) to induce operational tolerance and reduce or eliminate maintenance immunosuppression — currently in clinical trial phases at select centers

• Regenerative nerve enhancement: Topical or systemic neurotrophin-3 (NT-3) and GDNF delivery to accelerate axonal regeneration

• 3D-printed surgical planning models derived from CT angiography data for preoperative rehearsal of complex stump geometries

PHASE 1 — REMOTE EVALUATION (Weeks 1–4, before travel):

The patient submits medical records to GAF Healthcare, which are reviewed by the transplant surgical team. A virtual consultation is scheduled. If the patient is deemed a potential candidate, a formal work-up list is issued. Most baseline investigations (HLA typing, cardiac ECHO, NCS/EMG, infectious disease serology) can be completed at the patient's home country and uploaded securely. GAF Healthcare coordinates translation of all reports.

PHASE 2 — TRANSPLANT REGISTRATION & WAIT-LISTING (Variable, 1–18 months):

The patient travels to India or UAE for in-person assessment, psychiatric evaluation, cross-match testing, and formal listing on the hospital's deceased-donor VCA waitlist. Because hand transplant donors are rare (requiring a brain-dead donor with compatible limb anthropometry, blood group, and HLA), waiting periods are highly variable. During this phase, patients may return home and are placed on 24-hour call-back notice when a suitable donor is identified.

PHASE 3 — EMERGENCY TRAVEL ON DONOR IDENTIFICATION (48–72 hours):

When a compatible donor hand becomes available, GAF Healthcare activates the patient's rapid-travel protocol — emergency visa facilitation, flight booking, and airport transfer — with a target arrival at the transplant center within 4–6 hours of notification when possible.

PHASE 4 — PRE-OPERATIVE PREPARATION (24–48 hours before surgery):

• Final cross-match performed with donor lymphocytes

• Cardiac and anesthetic clearance

• Induction immunosuppression initiated (basiliximab or ATG)

• Bowel preparation, antibiotic prophylaxis (broad-spectrum, including anti-fungal coverage)

• Informed consent finalized

• Psychological support session

PHASE 5 — SURGICAL PROCEDURE (Day 0, 8–18 hours operative time):

Surgery performed under general endotracheal anesthesia. Sequential repair of bone, tendons, arteries, veins, and nerves as detailed in Treatment Options. The patient is transferred to the Transplant ICU on completion.

PHASE 6 — ICU MONITORING (Days 1–5):

• Hourly clinical assessment of hand perfusion (color, capillary refill, turgor, temperature, Doppler signal)

• Continuous implantable Doppler or NIRS monitoring

• Tacrolimus and MMF dose adjustment based on twice-daily trough levels

• IV anticoagulation (heparin infusion) titrated to PTT 50–70 seconds for first 72 hours, then transitioned to aspirin + low-molecular-weight heparin

• Vigilance for vascular thrombosis (requires emergency return to OR within 4–6 hours of detection for thrombectomy and reanastomosis)

• Pain management: multimodal (regional nerve blocks, IV opioids, IV paracetamol), transitioning to oral analgesia

PHASE 7 — WARD PHASE & EARLY REHABILITATION (Days 6–21):

• Oral immunosuppression consolidated; weekly tacrolimus trough monitoring

• First skin punch biopsy at Day 7–10 for Banff grading baseline

• Wound care and gentle dressing changes

• Hand therapy begins Day 5–7: passive range-of-motion exercises by certified hand therapist, edema management with elevation and compression

• Occupational therapy assessment: functional goal setting

• Nutritional support: dietitian-guided high-protein diet to support healing

• Patient and caregiver immunosuppression education sessions

PHASE 8 — EXTENDED INPATIENT/OUTPATIENT REHABILITATION (Weeks 4–12, in-country):

• Daily hand therapy: progression from passive to active-assisted to active range-of-motion

• Sensory re-education commences as protective sensation returns (usually Month 2–4)

• Muscle re-education using electromyographic (EMG) biofeedback

• Tacrolimus trough monitoring transitions to biweekly, then monthly

• Serial skin biopsies at Months 1, 3, and 6

• GAF Healthcare arranges outpatient physiotherapy at accredited facilities and hotel/apartment accommodation for the patient and accompanying caregiver

PHASE 9 — FIT-TO-FLY CLEARANCE & DEPARTURE (Weeks 10–16):

The transplant physician issues fit-to-fly clearance when all of the following are met:

• Stable tacrolimus trough levels within target range for ≥ 4 consecutive weeks

• No active rejection episode in the preceding 3 weeks

• Surgical wounds fully epithelialized

• No active infection

• Patient and home-country treating physician have received full immunosuppression protocol, biopsy schedule, and emergency contact plan

• GAF Healthcare arranges onward medical record transfer and a telemedicine follow-up schedule

PHASE 10 — LONG-TERM RECOVERY (Months 4–36, at home with remote monitoring):

• Nerve regeneration continues; protective sensation typically by Month 6–12, discriminative touch and intrinsic muscle activation by Month 18–36

• Annual in-person review at the transplant center (GAF Healthcare facilitates return travel coordination)

• Lifelong tacrolimus, MMF, and low-dose prednisolone — non-negotiable; graft loss rate rises sharply with non-adherence

• Ongoing physiotherapy and occupational therapy at home center

• Cortical remapping monitored via fMRI in select research-affiliated programs